BCM
KYNB

Blume Capital Management’s Kyntra Bio KYNB Stock Holding History

Blume Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed -$5K – 316
2022
Q2 		$5K Hold
20
– – ﹤0.01% 276
2022
Q1 		$6K Buy
+20
New +$6.97K ﹤0.01% 277

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Blume Capital Management's KYNB Position: Q3 2022 in Review

Blume Capital Management sold out of Kyntra Bio (KYNB) in Q3 2022, closing a stake of 20 shares — an estimated $5K sold.

Blume Capital Management first reported a position in KYNB in Q1 2022 and held it in 2 quarters. The position peaked at $6K in Q1 2022. 152 funds tracked by Wall St. Rank hold KYNB as of Q3 2022.

  • Blume Capital Management reported no remaining Kyntra Bio position as of Q3 2022 after selling out during the quarter.
  • Blume Capital Management sold 20 Kyntra Bio shares in Q3 2022, an estimated $5K.
  • Blume Capital Management first reported a position in Kyntra Bio in Q1 2022 and held it in 2 quarters.
  • Blume Capital Management's Kyntra Bio position peaked at $6K in Q1 2022.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2022.

Based on Blume Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.